Latest Breaking News On - Allogene therapeutics - Page 17 : comparemela.com

Zacks Research Research Analysts Raise Earnings Estimates for Allogene Therapeutics, Inc (NASDAQ:ALLO)

Zacks Research Research Analysts Raise Earnings Estimates for Allogene Therapeutics, Inc (NASDAQ:ALLO)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Millennium managementAllogene therapeutics company profileVanguard group incAllogene therapeutics incZacks researchJpmorgan chase coAllogene therapeuticsFree reportAllogene therapeuticGet free reportStreet corpAllogene therapeutics daily

Allogene Therapeutics (NASDAQ:ALLO) Coverage Initiated by Analysts at Citigroup

Citigroup started coverage on shares of Allogene Therapeutics (NASDAQ:ALLO – Free Report) in a research note released on Friday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $7.00 target price on the stock. ALLO has been the topic of a number of other research reports. JPMorgan Chase & Co. cut their […]

Blackrock incPricet rowe associates incJpmorgan chase coAllogene therapeutics incAllogene therapeuticsFree reportMarketbeat ratingsModerate buyTherapeutics stock downGet free reportStreet corpPricet rowe associatesAllogene therapeutics dailyNasdaq alloInitiated coverageCitigroup inc

Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology

Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoSouth san franciscoMadeleine goldsteinZachary robertsLeslie bryantAllogene alloChristine cassianoCompany received fast track designationNovartis pharmaceuticals corpKite pharma incJuno therapeutics incDrug administrationResearch developmentCorporate affairs brand strategyInternational conference on malignant lymphoma

Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology

Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

South san franciscoUnited statesSan diegoAllogene alloLeslie bryantZachary robertsMadeleine goldsteinChristine cassianoInternational conference on malignant lymphomaJuno therapeutics incMeeting of the american society hematologyCompany received fast track designationAllogene therapeutics incCorporate affairs brand strategyNovartis pharmaceuticals corpKite pharma inc

Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology

Comprehensive Review of All Patients in the Phase 1 ALPHA/ALPHA2 Trials Demonstrate that Adding Investigational ALLO-647 to Standard Lymphodepletion Can Yield Durable Responses and a Safety Profile.

United statesSan diegoSouth san franciscoMadeleine goldsteinLeslie bryantChristine cassianoZachary robertsAllogene alloResearch developmentCorporate affairs brand strategyKite pharma incDrug administrationInternational conference on malignant lymphomaCompany received fast track designationAmerican society of hematologyNovartis pharmaceuticals corp